59513Toplam
0Olumlu
0Olumsuz
50Nötr
Sayfa 189 / 1191 · toplam 59513 haber
▼
—
Braze, Inc. Q2 2027 Earnings Call Summary
Bu özet yapay zekâ ile otomatik üretildi
Braze, Inc. Q2 2027 Earnings Call Summary
▼
—
MIND Technology, Inc. Q2 2027 Earnings Call Summary
Bu özet yapay zekâ ile otomatik üretildi
MIND Technology, Inc. Q2 2027 Earnings Call Summary
▼
—
J.Jill, Inc. Q2 2027 Earnings Call Summary
Bu özet yapay zekâ ile otomatik üretildi
J.Jill, Inc. Q2 2027 Earnings Call Summary
▼
—
Is TE Connectivity Stock Underperforming the Dow?
Bu özet yapay zekâ ile otomatik üretildi
Is TE Connectivity Stock Underperforming the Dow?
▼
—
Wall Street’s Leveraged ETF Push Gets New Twist With Hourly Bets - Bloomberg.com
Bu özet yapay zekâ ile otomatik üretildi
Wall Street’s Leveraged ETF Push Gets New Twist With Hourly Bets Bloomberg.com
▼
—
Wall Street’s Leveraged ETF Push Gets New Twist With Hourly Bets - Bloomberg.com
Bu özet yapay zekâ ile otomatik üretildi
Wall Street’s Leveraged ETF Push Gets New Twist With Hourly Bets Bloomberg.com
▼
—
Wall Street’s Leveraged ETF Push Gets New Twist With Hourly Bets
Bu özet yapay zekâ ile otomatik üretildi
Wall Street’s Leveraged ETF Push Gets New Twist With Hourly Bets
▼
—
Ollie's (OLLI) Q2 2027 Earnings Call Transcript
Bu özet yapay zekâ ile otomatik üretildi
Ollie's (OLLI) Q2 2027 Earnings Call Transcript
▼
—
G-III Apparel (GIII) Q2 2027 Earnings Call Transcript
Bu özet yapay zekâ ile otomatik üretildi
G-III Apparel (GIII) Q2 2027 Earnings Call Transcript
▼
—
Daktronics (DAKT) Q1 2027 Earnings Call Transcript
Bu özet yapay zekâ ile otomatik üretildi
Daktronics (DAKT) Q1 2027 Earnings Call Transcript
▼
—
Cerebras Stock Is Under Pressure, But Cathie Wood Bets $17.2 Million On It
Bu özet yapay zekâ ile otomatik üretildi
Cerebras Stock Is Under Pressure, But Cathie Wood Bets $17.2 Million On It
▼
—
Alabama bank blasts investors’ request to join board
Bu özet yapay zekâ ile otomatik üretildi
Alabama bank blasts investors’ request to join board
▼
—
Forget Oklo: This Nuclear Stock Could Be the Better Buy
Bu özet yapay zekâ ile otomatik üretildi
Forget Oklo: This Nuclear Stock Could Be the Better Buy
▼
—
Is Cencora Stock Underperforming the Dow?
Bu özet yapay zekâ ile otomatik üretildi
Is Cencora Stock Underperforming the Dow?
▼
—
Is Realty Income Underperforming the Nasdaq?
Bu özet yapay zekâ ile otomatik üretildi
Is Realty Income Underperforming the Nasdaq?
▼
—
Bitcoin Price Swung 40% While Exchange Supply Rose 45,000 BTC: Is a Popular Onchain Signal Broken?
Bu özet yapay zekâ ile otomatik üretildi
Bitcoin Price Swung 40% While Exchange Supply Rose 45,000 BTC: Is a Popular Onchain Signal Broken?
▼
—
Novartis Heart Drug Failure Rattles Market for Rival Treatments - Bloomberg.com
Bu özet yapay zekâ ile otomatik üretildi
Novartis Heart Drug Failure Rattles Market for Rival Treatments Bloomberg.com
▼
—
Novartis Heart Drug Failure Rattles Market for Rival Treatments - Bloomberg.com
Bu özet yapay zekâ ile otomatik üretildi
Novartis Heart Drug Failure Rattles Market for Rival Treatments Bloomberg.com
▼
—
Bitcoin and ethereum prices today, Wednesday, September 9, 2026: Ongoing escalations in the Middle East are keeping a lid on crypto
Bu özet yapay zekâ ile otomatik üretildi
Bitcoin and ethereum prices today, Wednesday, September 9, 2026: Ongoing escalations in the Middle East are keeping a lid on crypto
▼
—
Google to Invest €13 Billion in AI Infrastructure in Finland - Bloomberg.com
Bu özet yapay zekâ ile otomatik üretildi
Google to Invest €13 Billion in AI Infrastructure in Finland Bloomberg.com
▼
—
NEWSLETTER: AstraZeneca drug reduces lung disease flare-ups in late-stage trials - reuters.com
Bu özet yapay zekâ ile otomatik üretildi
NEWSLETTER: AstraZeneca drug reduces lung disease flare-ups in late-stage trials reuters.com
▼
—
NEWSLETTER: AstraZeneca drug reduces lung disease flare-ups in late-stage trials - reuters.com
Bu özet yapay zekâ ile otomatik üretildi
NEWSLETTER: AstraZeneca drug reduces lung disease flare-ups in late-stage trials reuters.com
▼
—
NEWSLETTER: AstraZeneca drug reduces lung disease flare-ups in late-stage trials - reuters.com
Bu özet yapay zekâ ile otomatik üretildi
NEWSLETTER: AstraZeneca drug reduces lung disease flare-ups in late-stage trials reuters.com
▼
—
COMMENTARY: Morning Bid: Tit for tat - Reuters
Bu özet yapay zekâ ile otomatik üretildi
COMMENTARY: Morning Bid: Tit for tat Reuters
▼
—
Best CD rates today, Wednesday, September 9, 2026: Earn up to 4.35% APY with Marcus
Bu özet yapay zekâ ile otomatik üretildi
Best CD rates today, Wednesday, September 9, 2026: Earn up to 4.35% APY with Marcus
▼
—
Ask an Advisor: I'm 67 With $218k in an IRA. Should I Withdraw Money Now to Reduce Future RMD Taxes?
Bu özet yapay zekâ ile otomatik üretildi
Ask an Advisor: I'm 67 With $218k in an IRA. Should I Withdraw Money Now to Reduce Future RMD Taxes?
▼
—
European Luxury-Goods Stocks Face a Tough Second Half, HSBC Says - Bloomberg.com
Bu özet yapay zekâ ile otomatik üretildi
European Luxury-Goods Stocks Face a Tough Second Half, HSBC Says Bloomberg.com
▼
—
European Luxury-Goods Stocks Face a Tough Second Half, HSBC Says - Bloomberg.com
Bu özet yapay zekâ ile otomatik üretildi
European Luxury-Goods Stocks Face a Tough Second Half, HSBC Says Bloomberg.com
▼
—
Elon Musk Grok AI Predicts $250K Bitcoin Price by 2027
Bu özet yapay zekâ ile otomatik üretildi
Elon Musk Grok AI Predicts $250K Bitcoin Price by 2027
▼
—
EMIPA produces first gold-silver doré bar at Don Mario, Bolivia
Bu özet yapay zekâ ile otomatik üretildi
EMIPA produces first gold-silver doré bar at Don Mario, Bolivia
▼
—
Larger Deals Drive Q2 CRE Transaction Volume Higher
Bu özet yapay zekâ ile otomatik üretildi
Larger Deals Drive Q2 CRE Transaction Volume Higher
▼
—
Should You Buy Intel Stock After a Nearly Fourfold Year?
Bu özet yapay zekâ ile otomatik üretildi
Should You Buy Intel Stock After a Nearly Fourfold Year?
▼
—
Amazon Is Selling Its First Sterling Bonds in Four-Part Deal
Bu özet yapay zekâ ile otomatik üretildi
Amazon Is Selling Its First Sterling Bonds in Four-Part Deal
▼
—
Centerspace, Independence Realty Trust merge to create $8.1B REIT
Bu özet yapay zekâ ile otomatik üretildi
Centerspace, Independence Realty Trust merge to create $8.1B REIT
▼
—
Rising Oil Prices Threaten China’s Independent Refiners
Bu özet yapay zekâ ile otomatik üretildi
Rising Oil Prices Threaten China’s Independent Refiners
▼
—
Google to invest $15 billion AI infrastructure in Finland
Bu özet yapay zekâ ile otomatik üretildi
Google to invest $15 billion AI infrastructure in Finland
▼
—
We'll Earn More Than $300,000 This Year. Can a Backdoor Roth Help Reduce Our Taxes?
Bu özet yapay zekâ ile otomatik üretildi
We'll Earn More Than $300,000 This Year. Can a Backdoor Roth Help Reduce Our Taxes?
▼
—
Kraft Heinz Stock: Is KHC Underperforming the Consumer Defensive Sector?
Bu özet yapay zekâ ile otomatik üretildi
Kraft Heinz Stock: Is KHC Underperforming the Consumer Defensive Sector?
▼
—
Arvinas (ARVN) Just Made Protein Degrader History With FDA Nod
Bu özet yapay zekâ ile otomatik üretildi
Arvinas (ARVN) Just Made Protein Degrader History With FDA Nod
▼
—
COMMENTARY: In a global economic heatwave, beware financial wildfires - Reuters
Bu özet yapay zekâ ile otomatik üretildi
COMMENTARY: In a global economic heatwave, beware financial wildfires Reuters
▼
—
Ryman (RHP) Completed its $1.38B Grande Lakes Orlando Acquisition. Can Initial Adjusted EBITDAre Support the Financing Burden?
Bu özet yapay zekâ ile otomatik üretildi
Ryman (RHP) Completed its $1.38B Grande Lakes Orlando Acquisition. Can Initial Adjusted EBITDAre Support the Financing Burden?
▼
—
Apogee (APOG) Agreed to Acquire GroGlass for Up to €62.5M. Can a High-Margin Niche Deliver the Promised Synergies?
Bu özet yapay zekâ ile otomatik üretildi
Apogee (APOG) Agreed to Acquire GroGlass for Up to €62.5M. Can a High-Margin Niche Deliver the Promised Synergies?
▼
—
FuelCell (FCEL) Reported $1.3B of Committed Backlog and $2.3B of Awarded Capacity Backlog. How Much Can Become Profitable Revenue?
Bu özet yapay zekâ ile otomatik üretildi
FuelCell (FCEL) Reported $1.3B of Committed Backlog and $2.3B of Awarded Capacity Backlog. How Much Can Become Profitable Revenue?
▼
—
Nasdaq (NDAQ), Dasseti Alımını Tamamlayarak eVestment'in Özel Piyasa Kapasitelerini Genişletti
Bu özet yapay zekâ ile otomatik üretildi
Nasdaq (NDAQ), Dasseti'yi satın alarak eVestment'in özel piyasa platformunu güçlendirdi.
▼
—
Holtec Nuclear, Nasdaq IPO'sunda 10,2 Milyar Dolar Değerleme Hedefliyor
Bu özet yapay zekâ ile otomatik üretildi
Holtec Nuclear, Nasdaq'ta gerçekleşecek IPO'da 10,2 milyar $ değerleme hedefliyor.
▼
—
Yatsen (YSG) Reported 40.4% Skincare Growth but a Larger GAAP Operating Loss. Can Portfolio Mix Outrun Marketing Intensity?
Bu özet yapay zekâ ile otomatik üretildi
Yatsen (YSG) Reported 40.4% Skincare Growth but a Larger GAAP Operating Loss. Can Portfolio Mix Outrun Marketing Intensity?
▼
—
Genworth (GNW) Added $500M to its Repurchase Authorization. Can Enact (ACT) Capital Returns Fund the Buybacks?
Bu özet yapay zekâ ile otomatik üretildi
Genworth (GNW) Added $500M to its Repurchase Authorization. Can Enact (ACT) Capital Returns Fund the Buybacks?
▼
—
Zscaler (ZS) Gelir ve ARR Büyümesini Bildirdi, İş Gücü Azaltma Planlıyor
Bu özet yapay zekâ ile otomatik üretildi
Zscaler (ZS) çeyrek gelir ve yıllık yinelenen gelirde (ARR) büyüme bildirdi; aynı zamanda iş gücünde azaltma planı açıkladı.
▼
—
Should You Buy BorgWarner Stock Because Its Share Count Keeps Shrinking?
Bu özet yapay zekâ ile otomatik üretildi
Should You Buy BorgWarner Stock Because Its Share Count Keeps Shrinking?
▼
—
This Dividend Stock Is Facing a Perfect Storm. It Could Be the Time to Press that “Sell” Button
Bu özet yapay zekâ ile otomatik üretildi
This Dividend Stock Is Facing a Perfect Storm. It Could Be the Time to Press that “Sell” Button
Sayfa 189 / 1191 · toplam 59513 haber
Yatırım tavsiyesi değildir. Bu sayfadaki Lothien sağlamlık skorları, DCF teorik değerler ve analizler yalnızca bilgilendirme amaçlıdır. Yatırım tavsiyesi niteliği taşımaz. SPK (Sermaye Piyasası Kurulu) düzenlemelerine tabidir. Yatırım kararlarınızı almadan önce lisanslı bir yatırım danışmanına başvurunuz. Geçmiş performans gelecekteki sonuçların garantisi değildir.